Navigation Links
Cornell makes cancer vaccine for clinical use
Date:8/20/2009

ITHACA, N.Y. The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant proteina cancer vaccinethat will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.

The melanoma trial is being conducted at New York University Medical Center, while the ovarian cancer vaccine trial is being conducted at the Roswell Park Cancer Institute in Buffalo, N.Y. The trials are assessing the safety and the anti-tumor immune response of the NY-ESO-1-specific therapeutic cancer vaccine alone and in combination with other agents, according to the Cancer Research Institute (CRI), an organization that has recently given $450,000 to Cornell to support vaccine production at the Facility.

The goal of these trials is to maximize the body's immune response to the NY-ESO-1 protein. "Making NY-ESO-1 available for these clinical trials allows investigators to test ways to develop effective cancer vaccines," says Carl A. Batt, Cornell Liberty Hyde Bailey Professor of Food Science and director of the Bioproduction Facility.

Batt says: "This vaccine is not intended to prevent cancer, but one that will stimulate the body to fight an existing tumor. The challenge is that the vaccine is made from moleculesproteinsthat are found in our own bodies and do not normally induce strong immune responses. So part of this trial is to understand how to make the body react to these molecules and attack the cancer."

In 1997, Lloyd J. Old, then-scientific director of the Ludwig Institute for Cancer Research Ltd (LICR), and Yao-Tseng Chen, surgical and molecular pathologist at the Weill Cornell Medical College in New York City, discovered the NY-ESO-1 cancer/testis antigen, which has been found to be expressed by many different cancer types. NY-ESO-1 has been the central focus of the CRI/LICR Cancer Vaccine Collaborative, a global network of laboratory and clinical scientists devoted to the development of cancer vaccines. The immune-boosting effect of NY-ESO-1 vaccines has been studied in more than 40 early phase, single-variable clinical trials. The Cornell NY-ESO-1 protein will be used in other Cancer Vaccine Collaborative clinical trials around the world.

Nasser Altorki, a professor of cardiothoracic surgery and the director of the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center, performed some of the earliest NY-ESO-1 vaccine trials.

When the Bioproduction Facility opened in 2002, Old, director of the Ludwig Institute Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center in New York, and Hunter R. Rawlings III, then-president of Cornell University, challenged the traditional view that making therapeutic cancer products for human testing is the sole territory of pharmaceutical and biotechnology companies. This project has helped show that academic institutions can substantially participate in drug development.

The Ludwig Institute for Cancer Research provided the initial $2 million to create the Bioproduction Facility, and continues to fund its ongoing operations with recent additional support from The Atlantic Philanthropies. Since then, professional staff and Cornell graduate and undergraduate students have operated the facility. This Good Manufacturing Practice (GMP) facility was created behind the nearly century-old faade of Stocking Hall (in which Cornell students once took dairy-science classes). It consists of a series of clean rooms, where particulates even smaller than bacteria are filtered. Strict GMP regulations, administered by the U.S. Food and Drug Administration, are used by pharmaceutical, medical device and food manufacturers as they produce and test products.

The effort to bring the laboratory and production unit from idea to reality was led by Batt, Old, and Gerd Ritter, associate director of the LICR New York Branch. Initial discussions to create a facility began between Cornell and LICR in 1998. By the following year, Cornell had signed an agreement with LICR to create it.

Regarding this protein batch now going into clinical trial, Batt says, "We don't expect miracles, but the current array of surgical, radiation and chemotherapy options are not going to eliminate all types of cancers. What these cancer vaccines offer is another tool to help combat cancer, which can be used in conjunction with other existing therapeutic options. Also, bringing together our cancer vaccine development efforts in Ithaca with the clinical research programs of Drs. Nasser Altorki, Yao Chen, and their colleagues at the university's medical school in New York City represents an excellent model for integrating activities at the two campuses."


'/>"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-254-8093
Cornell University
Source:Eurekalert

Related medicine news :

1. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
2. Healthy restaurants help make us fat, says a new Cornell study
3. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
4. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
5. Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis
6. NewYork-Presbyterian/Weill Cornell creates world-class cancer center
7. By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis
8. $50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center
9. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
10. Weill Cornell receives funding to study creation of new elder abuse center
11. Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology: